Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after short-term treatment with intravitreous bevacizumab


Autoria(s): Fusco, Maria Alice; Freire Portes, Andre Luis; Allodi, Silvana; de Moraes Junior, Haroldo Vieira; Ribeiro Monteiro, Mario Luiz; de Oliveira Miguel, Nadia Campos
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

23/10/2013

23/10/2013

2012

Resumo

OBJECTIVE: Bevacizumab has been widely used as a vascular endothelial growth factor antagonist in the treatment of retinal vasoproliferative disorders in adults and, more recently, in infants with retinopathy of prematurity. Recently, it has been proposed that vascular endothelial growth factor acts as a protective factor for neurons and glial cells, particularly in developing nervous tissue. The purpose of this study was to investigate the effects of bevacizumab on the developing retinas of juvenile rabbits. METHODS: Juvenile rabbits received bevacizumab intravitreously in one eye; the other eye acted as an untreated control. Slit-lamp and fundoscopic examinations were performed both prior to and seven days after treatment. At the same time, retina samples were analyzed using immunohistochemistry to detect autophagy and apoptosis as well as proliferation and glial reactivity. Morphometric analyses were performed, and the data were analyzed using the Mann-Whitney U test. RESULTS: No clinical abnormalities were observed in either treated or untreated eyes. However, immunohistochemical analyses revealed a reduction in the occurrence of programmed cell death and increases in both proliferation and reactivity in the bevacizumab-treated group compared with the untreated group. CONCLUSIONS: Bevacizumab appears to alter programmed cell death patterns and promote gliosis in the developing retinas of rabbits; therefore, it should be used with caution in developing eyes.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasilia

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasilia

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Rio de Janeiro State Foundation for the Advancement of Science (FAPERJ)

Rio de Janeiro State Foundation for the Advancement of Science (FAPERJ)

Jose Bonifacio Foundation (FUJB)

Jose Bonifacio Foundation (FUJB)

Federal University of Rio de Janeiro Research Chamber, Brazil [SR2/UFRJ]

Federal University of Rio de Janeiro Research Chamber, Brazil

Identificador

CLINICS, SAO PAULO, v. 67, n. 1, supl., Part 3, pp. 61-67, 37316, 2012

1807-5932

http://www.producao.usp.br/handle/BDPI/35598

10.6061/clinics/2012(01)10

http://dx.doi.org/10.6061/clinics/2012(01)10

Idioma(s)

eng

Publicador

HOSPITAL CLINICAS, UNIV SAO PAULO

SAO PAULO

Relação

CLINICS

Direitos

openAccess

Copyright HOSPITAL CLINICAS, UNIV SAO PAULO

Palavras-Chave #BEVACIZUMAB #GLIAL CELLS #PROGRAMMED CELL DEATH #RETINA #RETINOPATHY OF PREMATURITY #GROWTH FACTOR-A #MULLER CELLS #MACULAR DEGENERATION #ENDOTHELIAL-CELLS #INJECTION #AVASTIN #AUTOPHAGY #TOXICITY #EYE #PHOTORECEPTORS #MEDICINE, GENERAL & INTERNAL
Tipo

article

original article

publishedVersion